HIND
NASDAQ · Pharmaceuticals
Vyome Holdings Inc
$2.12
-0.05 (-2.30%)
Financial Highlights (FY 2026)
Revenue
1.04M
Net Income
-33,323,971
Gross Margin
68.4%
Profit Margin
-3,209.8%
Rev Growth
-69.5%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 68.4% | 68.4% | 51.8% | 51.8% |
| Operating Margin | -3,269.4% | -2,942.5% | 18.6% | 21.0% |
| Profit Margin | -3,209.8% | -3,049.3% | 20.8% | 19.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.04M | 3.40M | 5.84M | 4.87M |
| Gross Profit | 710.3K | 2.33M | 3.02M | 2.52M |
| Operating Income | -33,937,575 | -100,045,258 | 1.09M | 1.02M |
| Net Income | -33,323,971 | -98,236,403 | 1.21M | 947.3K |
| Gross Margin | 68.4% | 68.4% | 51.8% | 51.8% |
| Operating Margin | -3,269.4% | -2,942.5% | 18.6% | 21.0% |
| Profit Margin | -3,209.8% | -3,049.3% | 20.8% | 19.4% |
| Rev Growth | -69.5% | -69.5% | -9.0% | -7.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 7.09M | 8.20M |
| Total Equity | — | — | 9.03M | 10.37M |
| D/E Ratio | — | — | 0.79 | 0.79 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -33,903,701 | -105,497,923 | 1.81M | 1.57M |
| Free Cash Flow | — | — | 575.3K | 579.0K |